GEORGIA BOARD OF PHARMACY
Board Meeting
2 Peachtree Street, NW, 36th Floor
Atlanta, GA 30303
July 16, 2014
9:00 a.m.

The following Board members were present:
Al McConnell, Chairperson
Laird Miller, Vice-Chairperson
Jim Bracewell
Mike Faulk
Chris Jones
Tony Moye
Bob Warnock

Staff present:
Tanja Battle, Executive Director
Rick Allen, GDNA
Janet Wray, Senior Assistant Attorney General
Brandi Howell, Business Operations Specialist

Visitors:
Keith A. Warren
Douglas Brush
Blake Brookerd
Michael Capece
Kelly Dillon
Kimberly Young
Brett Smith
LuGina M. Harper, Prime Therapeutics
Rusty Lee, Elder Care
John Sisto, ESI
Stephanie Kozol, ESI
Robert Highsmith, ESI
Brad Borum, Kaiser
Ben DiMarco, Davita Rx
Helen Sloat, Nelson Mullins
Andy Freeman, GPHA

Chairperson McConnell established that a quorum was present and called the meeting to order at 9:01 a.m.

Chris Jones made a motion and Jim Bracewell seconded, and the Board voted to enter into **Executive Session** in accordance with O.C.G.A. § 43-1-19(h)(2) and §43-1-2(k) to deliberate and to receive information on applications, investigative reports and the Assistant Attorney General's report. Voting in favor of the motion were those present who included Al McConnell, Laird Miller, Jim Bracewell, Mike Faulk, Chris Jones, Tony Moye and Bob Warnock.

Executive Session

Appearances

- K.A.W.
- M.B.B.
- K.D.D.
- K.S.Y.

Attorney General's Report – Janet Wray

Ms. Wray discussed the following case:

- J.A. and M.P.

No votes were taken in Executive Session. Chairperson McConnell declared the meeting back in Open Session.

Public Hearing

Chairperson McConnell called the Public Hearing to order at 11:03 a.m.

Representative Buddy Harden spoke to the Board regarding the proposed rules. He commended the Board for its efforts as it relates to non-resident and mail order pharmacies. He also thanked the Board for allowing him to speak today and for protecting the safety and welfare of the public.

Rule 480-6-.02 Nonresident Pharmacy Permit
No comments were received. A written response from Stephen Georgeson, Georgia Association of Chain Drug Stores was received.

Rule 480-34-.04 Synthetic Cannabinoids
No comments or written responses were received.

Rule 480-48-.01 Definitions
No comments were received. Written responses were received from the following:

- John Sisto
- Allen K. Horne, CVS Caremark
- Benjamin DiMarco, DaVita Rx

Rule 480-48-.02 Conditions for Use of Delivery by Mail
No comments were received. Written responses were received from the following:

- Vimal Parag, Health Mart Pharmacy of Johns Creek
- Dale Coker
- Clayton D. Edwards, Optum Rx
- John Sisto
- Allen K. Horne, CVS Caremark
- Stephen Georgeson, Georgia Association of Chain Drug Stores

Mr. Miller commented that the Board has received quite a few comments and there have been quite a few conversations regarding Rules 480-6-.02, 480-48-.01 and 480-48-.02. He went on to state that there is a feeling among the Board that some of these comments have some merit and he would like to suggest that the Board not take any action on the proposed rules today. He stated that the Board needs to take additional time to consider these comments.

Bob Warnock made a motion to table Rule 480-6-.02 Nonresident Pharmacy Permit. Jim Bracewell seconded and the Board voted unanimously in favor of the motion.

Laird Miller made a motion to table Rule 480-48-.02 Conditions for Use of Delivery by Mail. Tony Moye seconded and the Board voted unanimously in favor of the motion.

Chris Jones made a motion to table Rule 480-48-.01 Definitions. Jim Bracewell seconded and the Board voted unanimously in favor of the motion.

Tony Moye made a motion to adopt Rule 480-34-.04 Synthetic Cannabinoids. Chris Jones seconded and the Board voted unanimously in favor of the motion.

The hearing was adjourned at 11:14 a.m.

Open Session

Approval of Minutes
Jim Bracewell made a motion to approve the Public and Executive Session minutes for the June 17, 2014 meeting. Laird Miller seconded and the Board voted unanimously in favor of the motion.

Ratifications
Chris Jones made a motion to ratify the list of issued licenses. Jim Bracewell seconded and the Board voted unanimously in favor of the motion.

Petition for Rule Waiver – Jasvin Amin Merchant
Laird Miller made a motion to grant the rule waiver petition. Chris Jones seconded and the Board voted unanimously in favor of the motion.

Petition for Rule Waiver – Loretta Bibby
Tony Moye made a motion to deny the rule waiver petition. Mike Faulk seconded and the Board voted unanimously in favor of the motion.

Petition for Rule Waiver – Medtronic USA, Inc.
Laird Miller made a motion to deny the rule waiver petition. Chris Jones seconded and the Board voted unanimously in favor of the motion.

Petition for Rule Variance – Linda Flores Kropp
Jim Bracewell made a motion to grant the rule variance petition. Mike Faulk seconded and the Board voted unanimously in favor of the motion.

Petition for Rule Waiver – Marcia R. Greenwood
Mike Faulk made a motion to deny the rule waiver petition. Tony Moye seconded and the Board voted unanimously in favor of the motion.

Petition for Rule Waiver – Manzil Panchal
Mike Faulk made a motion to grant the rule waiver petition. Chris Jones seconded and the Board voted unanimously in favor of the motion.

Correspondence from Billy T. Green, Jr., RPH016485
The Board considered this correspondence from Mr. Green requesting to terminate probation. Tony Moye made a motion to approve the request. Mike Faulk seconded and the Board voted unanimously in favor of the motion.

Correspondence from Ken Wells, Oregon State University-College of Pharmacy
The Board considered this correspondence regarding online continuing education courses. Bob Warnock made a motion to approve the course. Chris Jones seconded and the Board voted unanimously in favor of the motion.

Correspondence from Anthony Ortiz
The Board considered this correspondence regarding whether a veterinary reference laboratory that formulates veterinary biological products falls within the purview of the Georgia Board of Pharmacy's regulatory authority, or whether the client needs to be licensed as a pharmacy in Georgia. Chris Jones

made a motion to direct staff to respond to Mr. Ortiz by referring him to the law and rules located on the Board's website and to suggest the client consult with an attorney as to what type of licensure would be required prior to distributing dangerous drugs into this state.

Correspondence from Charles E. Termini

The Board considered this correspondence regarding Medication Therapy Management services. Chris Jones made a motion to direct staff to respond to Mr. Termini by stating that he did not provide sufficient information for the Board to make a determination and suggest he review the law and rules located on the Board's website and resubmit his request. Laird Miller seconded and the Board voted unanimously in favor of the motion.

Correspondence from John E. Morrone on behalf of Florida Pharmacy Solutions, Inc.

The Board considered this correspondence requesting to know if Florida Pharmacy Solutions, Inc. would be permitted to participate in office use compounding and deliver such samples to Georgia prescribers for use and development of customized medications for each individual patient. Chris Jones made a motion to direct staff to respond by stating that Florida Pharmacy Solutions, Inc. may not deliver the drugs or their samples into this State without the appropriate license and suggest they review the law and rules located on the Board's website for additional information. Mike Faulk seconded and the Board voted unanimously in favor of the motion.

Georgia Drugs and Narcotics Agency – Rick Allen

No report.

Executive Director's Report – Tanja Battle

No report.

Miscellaneous

The Board discussed possible dates for the monthly board meeting in January and the practical examination that will be held at Mercer University. The Board recommended January 21, 2015 for the meeting and January 22, 2015 for the practical examination.

Mike Faulk made a motion to post Rule 480-22-.04 Requirements of a Schedule II (C-II) Controlled Substance Prescription Drug Order. Tony Moye seconded and the Board voted unanimously in favor of the motion.

480-22-.04 Requirements of a Schedule II (C-II) Controlled Substance Prescription Drug Order.

(1) A pharmacist or pharmacy intern/extern shall dispense a schedule II Controlled Substance (C-II), as defined by O.C.G.A. § 16- 13-26, only pursuant to a written prescription drug order, except as provided in paragraph (3) of this Rule.

(a) A C-II prescription drug order, meeting the requirements of Rule 480-22-.03(1)(a), may be transmitted by the practitioner or the practitioner's agent, to a pharmacy via facsimile machine or equipment. Prior to the practitioner's agent transmitting such schedule II (C-II) prescription via facsimile machine, the C-II prescription drug order, meeting the requirements of Rule 480-22-.03(1)(a), may be transmitted by the practitioner or the practitioner's agent, but not the patient or patient's agent, to a pharmacy via facsimile machine or equipment. The original written, signed prescription drug order must be presented to the pharmacist prior to the actual dispensing of the schedule II (C-II) drug, except as provided in paragraphs (4), (5) or (6) of this section.

(2) Upon dispensing a schedule II (C-II) drug, the pharmacist shall physically sign his or her name on either the face or rear of the schedule II (C-II) prescription drug order in such a manner that the signature does not cover any information required by this chapter. In addition, the pharmacist will ensure that the dispensing date and the serial number for the prescription drug order are indicated on either the face or the back of the C-II prescription drug order.

(3) In the case of an emergency situation, a pharmacist may dispense a schedule II (C-II) controlled substance only upon receiving oral authorization of the prescribing practitioner. For purposes of this paragraph, an emergency situation means a situation in which the prescribing practitioner determines that immediate administration of a schedule II (C-II) controlled drug is necessary, there is no appropriate alternative treatment or drug in a schedule less than CII, and it is not reasonably possible for the practitioner to provide a written prescription drug order for the pharmacist dispensing the drug prior to issuance. Such emergency prescription drug order is permissible provided that:
(a) The quantity prescribed and dispensed is limited to the amount adequate to treat the patient during the emergency period. Dispensing beyond the emergency period must be pursuant to an additional written prescription drug order signed by the prescribing practitioner;
(b) The prescription drug order shall be immediately reduced to writing by the pharmacist or pharmacy intern/extern working under the direct supervision of a licensed pharmacist and shall contain all information required in Rule 480-22-.03, except for the signature of the prescribing practitioner;
(c) If the prescribing practitioner is not known to the pharmacist, the pharmacist must make reasonable effort to determine that the oral authorization came from a licensed practitioner, such effort may include a callback to the prescribing individual using his or her telephone number and/or other good faith efforts to insure the practitioner's identity; and
(d) Within 7 days after authorizing an emergency oral prescription drug order, the prescribing practitioner shall cause a written prescription drug order to be delivered to the dispensing pharmacist for the emergency quantity prescribed. In addition to conforming to the requirements of Rule 480-22-.03, the prescription shall have written on its face "Authorization for Emergency Dispensing," and the date of the oral order.
1. The written prescription drug order shall be delivered to the pharmacist in person or by other means, but if delivered by mail or common carrier it must be postmarked within the 7 day period. Upon receipt, the dispensing pharmacist shall attach this prescription drug order to the emergency oral prescription drug order, which had earlier been reduced to writing. The pharmacist shall notify the Georgia Drugs and Narcotics Agency, if the prescribing practitioner fails to deliver a written prescription drug order to the dispensing pharmacist.
(4) A prescription drug order for a terminally ill patient, prepared in accordance with Rule 480-22-.03 written for a Schedule II Controlled Substance as defined by O.C.G.A. §16-13-26, may be transmitted directly by the practitioner or the practitioner's agent to the dispensing pharmacy by facsimile machine.
(a) Prior to the prescribing practitioner's agent transmitting such Schedule II Controlled Substance prescription via facsimile machine, the name of the agent and a telephone number for the prescribing practitioner must be included in the face of prescription. The information may be used for verification of the prescription.
(b) The facsimile serves as the original, written prescription drug order for purposes of this paragraph, and it shall be maintained in accordance with Rule 480-22-.04(7) and this chapter. After transmission of the original prescription, the pharmacist should suggest that the practitioner mark "VOID" across the face of the prescription, and that it be maintained by the practitioner in the patient's medical record chart.
(5) A prescription drug order prepared in accordance with Rule 480-22-.04 written for any C-II substance for a resident of Long Term Care Facility (LTCF) may be transmitted directly by the prescribing practitioner or the practitioner's agent, but not the patient or the patient's agent, to the dispensing pharmacy by facsimile machine or equipment.
(a) The practitioner or practitioner's agent will note on the prescription drug order that the patient is a LTCF patient by writing "LTCF" on the face of the prescription.
(b) In addition to the term LTCF being noted on the face of the prescription, whenever a practitioner's agent transmits such a prescription, the name of the agent and the practitioner's telephone number must be included on the face of the prescription. This information may be used for verification of the prescription drug order.
(c) The facsimile serves as the original, written prescription drug order for purposes of this paragraph (c), and it shall be maintained in accordance with Rule 480-22-.04(a) and this chapter. After

transmission of the original prescription, the pharmacist should suggest that the practitioner mark "VOID" across the face of the prescription, and that it be maintained by the practitioner in the patient's medical record chart.
(6) A prescription drug order prepared in accordance with Rule 480-22-.03 written for any Schedule II Controlled Substance as defined by O.C.G.A. § 16-13-26, for a patient of a hospice program licensed by the State of Georgia Department of Human Resources may be directly transmitted by the practitioner or the practitioner's agent, but not the patient or the patient's agent, to the dispensing pharmacy by facsimile machine or equipment.
(a) The practitioner or practitioner's agent will note on the prescription drug order that the patient is a hospice patient by writing "HOSPICE" on the face of the prescription.
(b) In addition to the term "HOSPICE" being noted on the face of the prescription, whenever a practitioner's agent transmits such prescription, the name of the agent and the practitioner's telephone number must be included on the face of the prescription. This information may be used for verification of the prescription drug order.
(c) The facsimile serves as the original, written prescription drug order for purposes of this paragraph, and it shall be maintained in accordance with Rule 480-22-.04(a) and this chapter. After transmission of the original prescription drug order, the pharmacist should suggest that the practitioner mark "VOID" across the face of the prescription, and that it be maintained by the practitioner in the patient's medical chart.
(7) Record keeping for Schedule II Controlled Substances shall be as follows:
(a) Original and all other hard copy schedule II (C-II) prescription drug orders shall be maintained in a separate file from all other prescription drug orders.
(b) Whenever a pharmacy utilizes a computerized record keeping system in addition to hard copies to record the dispensing of prescription drug orders for C-II drugs, such records shall be <u>immediately</u> retrievable without delay in a printout form by the prescribing practitioner's name, patient's name, drug name or date of dispensing upon a verbal request from a representative of the Georgia Drugs and Narcotics Agency (GDNA), and/or one of its agents. ~~When such computerized record keeping system is centralized and cannot produce on-site printouts, such printouts shall be provided within 48 hours of the original request.~~
(8) Whenever a pharmacist receives a prescription for a C-II controlled substance, and either the quantity of the drug to be dispensed or the strength of the drug to be dispensed has not been included by the prescribing practitioner, or when the strength of the prescribed drug is not immediately available, in order to dispense this drug, the pharmacist must perform the following:
(a) Contact and speak directly with the practitioner, not with an agent for the practitioner, and inform the practitioner of the missing information on the face of the prescription, or the problem with the prescription in question by:
1. Determining the quantity of the drug the practitioner intended to be dispensed; or
2. Determining the strength of the drug the practitioner intended to be dispensed; or
3. Informing the practitioner the drug in the strength prescribed is not immediately available, but another strength of the prescribed drug is available.
(b) Regarding the information provided by the practitioner, the pharmacist must write the missing quantity, the missing strength, or the changed quantity and strength of the prescribed drug on the face of the prescription along with the initials of the pharmacist.
(c) On the back of the prescription, the pharmacist must write the date and time the pharmacist spoke with the practitioner, along with a brief explanation of the situation and how it was resolved.
(d) Nothing in this rule is intended to require a pharmacist in a hospice or LTCF setting to obtain a new prescription drug order when changes are made to a patient's dosing requirements. This action may be taken as long as the pharmacist verifies the change(s) with the practitioner and makes a notation of the change(s) along with the date of the change(s) on the original hard-copy prescription drug order.
(9) A Schedule II narcotic controlled substance prescription prepared in accordance with Rule 480-22-.03 and as defined by O.C.G.A. § 16-13-26, to be compounded for the direct administration to a patient by parenteral, intravenous, intramuscular, subcutaneous or intraspinal infusion may be transmitted by

the practitioner or the practitioner's agent to the pharmacy by facsimile. The facsimile serves as the original written prescription for purposes of this rule and it shall be maintained in accordance with this rule and state and federal law.

Tony Moye made a motion to post Rule 480-27-.05 Record-Keeping When Utilizing an Automated Electronic Data Processing System. Mike Faulk seconded and the Board voted unanimously in favor of the motion.

480-27-.05 Record-Keeping When Utilizing an Automated Electronic Data Processing System.
In order to comply with the record keeping requirements of this Chapter, an automated electronic data processing system may be utilized for the record keeping system if the following conditions have been met:
(a) Except as otherwise provided herein, all original prescriptions, those hard copies written by a practitioner, telephoned to the pharmacist by a practitioner and reduced to writing, or sent via facsimile machine or other electronic means must be retained as a permanent record for two years in the usual consecutively serial numbered prescription file. Any refill information subsequently authorized by a practitioner must be maintained in the manner required by O.C.G.A. § 26-4-80(e).
(b) The system shall at a minimum produce sight-readable ~~printouts~~ records for all dangerous drug and controlled substance prescriptions filled or refilled during ~~for~~ each 24 hour period. The term "sight-readable" means that a representative of the Board or GDNA shall be able to ~~readily~~immediately retrieve and examine the record and read the information during any on-site visit to the pharmacy. For purposes of off-site audits and review, a separate copy of any sight-readable hard-copy printout or electronic readable file (such as a PDF file) of each daily record shall be made available to a representative of the Board of GDNA upon verbal request by that representative. These daily prescription records can:
1. Be generated as hard-copy print-outs at least once weekly, separated into each 24 hour period, by the pharmacy and maintained for at least two years after the last date on which the prescription was filled or refilled. If a hard-copy printout of each day's filled and refilled prescription is generated, that printout shall be verified, dated, and signed by the individual pharmacist who refilled such a prescription order. The individual pharmacist must verify that the data indicated are correct and then sign this document in the same manner as he would sign a check or legal document (*e.g.*, J.H. Smith, or John H. Smith). This document shall be maintained in a separate file at that pharmacy for a period of two years from the dispensing date; or
2. Be maintained electronically. The computers on which the records are maintained may be located at another location, but the records must be immediately retrievable as hard-copy print-outs or viewing on a computer monitor set aside for such viewing at each individually registered pharmacy upon a verbal request by a representative from the Board or GDNA. The computer software must be capable of printing out or transferring the prescription records in a format that is readily understandable to the representative for the Board or GDNA at the registered location. Prescription records must also be sortable and retrievable by prescriber name, patient name, drug dispensed, and date filled. When utilizing electronic daily prescription fill and refill records, each pharmacy shall maintain a bound log book, or separate file, in which each individual pharmacist involved in such dispensing shall sign a statement each day, attesting to the fact that the prescription information entered by him or her into the computer that day has been reviewed by him or her and is correct as shown. Such a book or file must be maintained at the pharmacy employing such software for a period of two years after the date of dispensing the appropriately authorized refill.

~~These print-outs must be generated at least once weekly by the pharmacy and maintained for at least two years after the last date on which the prescription was filled or refilled. If not readily retrievable, any such printouts shall be generated as soon as possible upon the verbal request from the Board or GDNA representative.~~

(c) The information maintained by the automated electronic data processing system shall include, but not be limited to the following:
1. Date of dispensing;
2. Prescription number;
3. Patient's name;
4. Patient's address;
5. Drug name, strength and dosage form;
6. Quantity prescribed, and if the quantity dispensed is different from the quantity prescribed, the quantity dispensed;
7. Prescriber's name;
8. Identification of dispensing pharmacist;
9. Indication whether drugs are being dispensed pursuant to a new prescription or for a refill order;
10. In case of a controlled substance as allowed by federal law, the name, address and DEA registration of the practitioner and the schedule of the drug;
11. Directions for administration of the prescription to the patient;
12. Total number of refills authorized; and
13. NPI of the prescriber as assigned under federal law.
(d) Permanent records of electronic prescriptions for dangerous drugs and controlled substances do not have to be reduced to hard copy provided the following requirements are met:
1. Electronic prescription data must be maintained in the original format received for a minimum of two years; and
2. Reliable backup copies of the information are readily retrievable and stored in a secure and fireproof (minimum 1 hr UL approved) container, stored in a secured offsite location or backed up to a documented offsite secure storage device within 48 hours following each work day.
(e) The individual pharmacist responsible for completeness and accuracy of the entries to the system must provide documentation that prescription information entered into the computer is correct, by dating and signing the print-out in the same manner as signing a check or legal document (e.g., Mary A. Smith or M. A. Smith).
(f) An auxiliary record-keeping system shall be established for the documentation of filling new prescriptions, refills, and transfers if the automated electronic data processing system is inoperative for any reason. The auxiliary system shall insure that all refills are authorized by the original prescription and that the maximum number of refills is not exceeded. When this automated electronic data processing system is restored to operation, the information regarding prescriptions filled and refilled during the inoperative period shall be entered into the automated electronic data processing system as soon as possible. However, nothing in this section shall preclude the pharmacist from using his/her professional judgment for the benefit of a patient's health and safety.
(g) Any pharmacy using an automated electronic data processing system must comply with all applicable State and Federal laws and regulations.
(h) A pharmacy shall make arrangements with the supplier of data processing services or materials to insure that the pharmacy continues to have adequate and complete prescription and dispensing records if the relationship with such supplier terminates for any reason. A pharmacy shall insure continuity in the maintenance of records.

A motion was made by Chris Jones, seconded by Mike Faulk, and the Board voted that the formulation and adoption of these amendments do not impose excessive regulatory cost on any licensee and any cost to comply with the proposed rule cannot be reduced by a less expensive alternative that fully accomplishes the objectives of the relevant code sections.

In the same motion, the Board voted that it is not legal or feasible to meet the objectives of the relevant code sections to adopt or implement differing actions for businesses as listed at O.C.G.A§ 50-13-9 16 5

4(a)(3)(A), (B), (C) and (D). The formulation and adoption of these rules will impact every licensee in the same manner and each licensee is independently licensed, owned and operated and dominant in the field of pharmacy.

Mike Faulk made a motion and Chris Jones seconded, and the Board voted to enter into **Executive Session** in accordance with O.C.G.A. § 43-1-19(h)(2) and §43-1-2(k) to deliberate and to receive information on applications, investigative reports and the Assistant Attorney General's report. Voting in favor of the motion were those present who included Al McConnell, Laird Miller, Jim Bracewell, Mike Faulk, Chris Jones, Tony Moye and Bob Warnock.

Executive Session

Attorney General's Report – Janet Wray
Ms. Wray resumed discussing the following case:

- J.A. and M.P.

Ms. Wray discussed the following case:

- C.H.

Ms. Wray presented the following consent orders:

- A.B.
- A.C.
- W.K.F.P.
- C.H.
- M.R.G.
- T.P.
- D.J.

Georgia Drugs and Narcotics Agency – Rick Allen
Discussed latest PDMP reports.

Applications
- L.N.P.
- T.D.
- Q.L.B.
- C.S.H.
- C.R.V.
- V.M.C.
- M.N.L.
- M.A.M.
- J.B.
- S.A.L.
- E.G.M.

Cognizant's Report – Laird Miller
- GDNA Case #A-31087
- GDNA Case #T14-21

- GDNA Case #T-31117
- GDNA Case #T31138
- GDNA Case #T-31147
- GDNA Case #T-31172
- GDNA Case #A14-24
- GDNA Case #A-31044
- GDNA Case #B30955
- GDNA Case #A14-15
- G.M.M.S.
- V.P.
- GDNA Case #A14-25

No votes were taken in Executive Session. Chairperson McConnell declared the meeting back in Open Session.

Open Session

The Board discussed the need to have a conference call in August so that it may vote to post Rules 480-6-.02, 480-48-.01 and 480-48-.02.

Laird Miller made a motion and Chris Jones seconded, and the Board voted to enter into **Executive Session** in accordance with O.C.G.A. § 43-1-19(h)(2) and §43-1-2(k) to deliberate and to receive information on applications, investigative reports and the Assistant Attorney General's report. Voting in favor of the motion were those present who included Al McConnell, Laird Miller, Jim Bracewell, Mike Faulk, Chris Jones, Tony Moye and Bob Warnock.

Executive Session

Executive Director's Report – Tanja Battle
Ms. Battle presented a recommendation regarding a personnel matter. The Board discussed this and two other matters related to personnel.

No votes were taken in Executive Session. Chairperson McConnell declared the meeting back in Open Session.

Open Session

Bob Warnock made a motion for the Board to take the following action:

Executive Director's Report – Tanja Battle
Approve recommendation of the Department of Community Health Commissioner.

Tony Moye seconded and the Board voted unanimously in favor of the motion.

Chris Jones made a motion and Jim Bracewell seconded, and the Board voted to enter into **Executive Session** in accordance with O.C.G.A. § 43-1-19(h)(2) and §43-1-2(k) to deliberate and to receive information on applications, investigative reports and the Assistant Attorney General's report. Voting in favor of the motion were those present who included Al McConnell, Laird Miller, Jim Bracewell, Mike Faulk, Chris Jones, Tony Moye and Bob Warnock.

Executive Session

Applications

- M.H.C.
- J.N.B.
- A.G.C.
- D.K.
- C.C.B.
- J.L.B.
- M.A.A.A.
- V.A.
- R.A.
- A.P.
- O.P.I.
- U.D.S.I.
- V.S.I.
- G.D.D.
- S.M.D.

Correspondences/Requests

- C.C.
- U.A.U.
- P.M.
- J.L.
- S.K.
- C.T.M.
- A.H.
- R.M.I.
- K.C.

Miscellaneous

- Eric Lacefield, Deputy Director, discussed the June examination and the upcoming August examination with the Board.
- Discussed wet lab vs. dry lab.

No votes were taken in Executive Session. Chairperson McConnell declared the meeting back in Open Session.

Open Session

Chris Jones made a motion for the Board to take the following actions:

Appearances

- K.A.W. Approved request to terminate probation
- M.B.B. No action taken
- K.D.D. Denial upheld
- K.S.Y. Denial upheld

Attorney General's Report – Janet Wray

Ms. Wray resumed discussing the following case:

- J.A. and M.P. Refer to Attorney General's office for discipline. Close case regarding J.A.

Ms. Wray discussed the following case:

- C.H. Close case and refer to GDNA for further investigation

Ms. Wray presented the following consent orders:

- A.B. Private Consent Order accepted
- Alex Chan Public Consent Order accepted
- Wai-Kiu Famcare Pharmacy Public Consent Order accepted
- C.H. Private Consent Order accepted
- M.R.G. Private Consent Order accepted
- T.P. Private Consent Order accepted
- D.J. Private Consent Order accepted

Georgia Drugs and Narcotics Agency – Rick Allen

Discussed latest PDMP reports. The Board suggested adding a question to the pharmacist renewal application that asks, "*Are you currently registered to use the Prescription Drug Monitoring Program (PDMP)? If no, you may register to use PDMP by going to http://www.hidinc.com/gapdmp."*

Applications

- Lashante N. Pryor Pharmacy Technician Approved registration
- Tahira Dawood Pharmacy Technician Approved registration
- Quonisha L. Butler Pharmacy Technician Approved registration
- C.S.H. Pharmacy Technician Denied registration
- C.R.V. Pharmacy Technician Approve pending receipt of additional information
- V.M.C. Pharmacy Technician Denied registration
- Megan N. Landaverde Pharmacy Technician Approved registration
- Mahamed A. Mousse Pharmacy Technician Approved registration
- J.B. Pharmacy Technician Denied registration
- S.A.L. Pharmacy Technician Allow applicant to withdraw application
- E.G.M. Pharmacy Technician Denied registration

Cognizant's Report – Laird Miller

- GDNA Case #A-31087 Refer to the Attorney General's office for discipline
- GDNA Case #T14-21 Revoke technician registration
- GDNA Case #T-31117 Revoke technician registration
- GDNA Case #T31138 Accept Voluntary Surrender
- GDNA Case #T-31147 Accept Voluntary Surrender
- GDNA Case #T-31172 Accept Voluntary Surrender upon receipt of the original
- GDNA Case #A14-24 Refer to the Attorney General's office for summary suspension
- GDNA Case #A-31044 Refer to the Attorney General's office for discipline

- GDNA Case #B30955 — No action taken
- GDNA Case #A14-15 — Refer to the Attorney General's office for summary suspension
- G.M.M.S. — Denied application
- V.P. — Denied application
- GDNA Case #A14-25 — Refer to the Attorney General's office for summary suspension

Applications

• M.H.C.	Pharmacist	Approved application
• J.N.B.	Pharmacist Reciprocity	Overturn denial and approve to sit for exam
• A.G.C.	Pharmacist	Table pending receipt of additional information
• D.K.	Pharmacist Reciprocity	Approved application
• Candice C. Bramlett	Pharmacist Intern	Approved application
• J.L.B.	Pharmacist Intern	Denied request for extension
• M.A.A.A.	Pharmacist Intern	Hours approved
• V.A.	Pharmacist Intern	Hours approved
• R.A.	Pharmacist Intern	Hours approved
• A.P.	Wholesaler Pharmacy	Denied application
• O.P.I.	Wholesaler Pharmacy	Refer to the Attorney General's office for discipline
• U.D.S.I.	Wholesaler Pharmacy	Refer to the Attorney General's office for discipline
• V.S.I.	Wholesaler Pharmacy	Refer to the Attorney General's office for discipline
• G.D.D.	Wholesaler Pharmacy	Letter of Concern
• S.M.D.	Inactive Status	Approved application

Correspondences/Requests

• C.C.	Notice of discipline	For informational purposes only
• U.A.U.	Request to lift probation	Approved request
• P.M.	Request to lift PIC restriction	Approved request
• J.L.	Correspondence	Directed staff to respond by stating that the Board is willing to consider the request
• S.K.	Correspondence	Directed staff to respond by stating that notification to the Board is not required under these circumstances
• C.T.M.	Correspondence	Table and allow applicant to sit for the examination
• A.H.	Request to lift work hour restriction	Denied request
• R.M.I.	Correspondence	Directed staff to respond by stating that a virtual manufacturer's license is not available in this State
• K.C.	Self-Report	Revoke technician registration

Miscellaneous

- Eric Lacefield, Deputy Director, discussed the June examination and the upcoming August examination with the Board. No action taken.
- Discussed wet lab vs. dry lab. Chairperson McConnell appointed Tony Moye and Mike Faulk to a Committee that will look into this matter further and report back to the Board in September.

Jim Bracewell seconded and the Board voted in favor of the motion, with the exception of Tony Moye, who abstained from the vote regarding P.M.

Mr. Miller requested the Board send a letter to the Dean of the College of Pharmacy at the University of Georgia complimenting him and his staff for their efforts during the June examination. He also requested the Board send a letter to Commissioner Clyde Reese, Department of Community Health, commending staff for their efforts with administering the examination. Mr. Miller stated he would be happy to draft the letters and submit them to Chairperson McConnell for signature.

Mr. Moye stated that he and Mr. Miller were contacted by PCOM concerning slides. The PCOM representative wanted to speak to a board member concerning what she should teach. Mr. Miller suggested she contact Judy Gardner regarding this matter as he does not know what kind of legal guidance the Board can give to her without compromising the integrity of the examination.

The Board discussed the issue of candidates bringing cell phones with them to the examination. Ms. Battle stated that staff will reword the letter that goes out to the candidate explaining that cell phones will not be allowed and that if the candidate is caught with a cell phone, he/she may be dismissed from the examination and will have to be rescheduled.

The next scheduled meeting of the Georgia Board of Pharmacy is scheduled for Wednesday, August 20, 2014, at 9:00 a.m. at South University College of Pharmacy, 709 Mall Blvd, Savannah, GA 31406.

The Board meeting adjourned at 3:50 p.m.

Minutes recorded by Brandi P. Howell, Business Operations Specialist
Minutes edited by Tanja D. Battle, Executive Director